Advertisement

How to Document a Clinical Study and Avoid Common Mistakes in Study Conduct?

  • Caroline MoutonEmail author
  • Laura De Girolamo
  • Daniel Theisen
  • Romain Seil
Chapter

Abstract

Study conduct is an important and sensitive part of a clinical research project. Adequate planning is paramount to avoid mistakes with potential legal or quality-related consequences. Principal investigators should comply with legal requirements to avoid an early discontinuation of the study. Regulatory binders should be available on-site at any time of the study both in case of an audit and to be consulted by the study team if required. All study activities, from patient eligibility check to data collection through informed consent and study visits, should be carefully planned and scheduled in agreement with the study team prior to first patient enrollment. To allow for a high-quality study, which would deserve to be published in a high-ranked journal, a professional preparation is the key to success.

Bibliography

  1. 1.
    ICH tripartite guideline for good clinical practices E6 (R1). 1996. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf.
  2. 2.
    NCCIH clinical research toolbox—essential documents/regulatory binder. https://nccih.nih.gov/grants/toolbox#binder.
  3. 3.
    (2016) regulation (EU) 2016/679 of the European Parliament and of the council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation). Official Journal L 119, 4.5.2016, p. 1–88. Official Journal L 119 1–88.Google Scholar
  4. 4.
    Administration USDoHaHSFaD. Guidance for industry—electronic source data in clinical investigations. 2013. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM328691.pdf.
  5. 5.
    Administration USDoHaHSFaD. Guidance for industry—investigator responsibilities—protecting the rights, safety, and welfare of study subjects. 2009. https://www.fda.gov/downloads/Drugs/.../Guidances/UCM187772.pdf.
  6. 6.
    Bargaje C. Good documentation practice in clinical research. Perspect Clin Res. 2011;2(2):59–63.CrossRefGoogle Scholar
  7. 7.
    Bellary S, Krishnankutty B, Latha MS. Basics of case report form designing in clinical research. Perspect Clin Res. 2014;5(4):159–66.CrossRefGoogle Scholar
  8. 8.
    Bhatt A. Protocol deviation and violation. Perspect Clin Res. 2012;3(3):117.CrossRefGoogle Scholar
  9. 9.
    Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, et al. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. BMJ. 2015;351:h5527.CrossRefGoogle Scholar
  10. 10.
    Chan AW, Tetzlaff JM, Gotzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586.CrossRefGoogle Scholar
  11. 11.
    Clark GT, Mulligan R. Fifteen common mistakes encountered in clinical research. J Prosthodont Res. 2011;55(1):1–6.CrossRefGoogle Scholar
  12. 12.
    Communication from the commission—detailed guidance on the request to the competent authorities for authorisation of a clinical trial on a medicinal product for human use tnos.Google Scholar
  13. 13.
    Theisen D, Moksnes H, Hardy C, Engebretsen L, Seil R. How to organise an international register in compliance with the European GDPR: walking in the footsteps of PAMI (Paediatric ACL Monitoring Initiative). Google Scholar
  14. 14.
    Decullier E, Lhéritier V, Chapuis F. The activity of French Research Ethics Committees and characteristics of biomedical research protocols involving humans: a retrospective cohort study. BMC Med Ethics. 2005;6:9.CrossRefGoogle Scholar
  15. 15.
    Elm JJ, Palesch Y, Easton JD, Lindblad A, Barsan W, Silbergleit R, et al. Screen failure data in clinical trials: are screening logs worth it? Clin Trials. 2014;11(4):467–72.CrossRefGoogle Scholar
  16. 16.
    FDA. Guidance for Institutional Review Boards and clinical investigators—recruiting study subjects—information sheet. 2018. https://www.fda.gov/RegulatoryInformation/Guidances/ucm126428.htm.
  17. 17.
    FDA. Guidance for Institutional Review Boards and clinical investigators—screening tests prior to study enrollment—information sheet. 2018. https://www.fda.gov/RegulatoryInformation/Guidances/ucm126430.htm.
  18. 18.
    Getz KA, Wenger J, Campo RA, Seguine ES, Kaitin KI. Assessing the impact of protocol design changes on clinical trial performance. Am J Ther. 2008;15(5):450–7.CrossRefGoogle Scholar
  19. 19.
    Getz KA, Zuckerman R, Cropp AB, Hindle AL, Krauss R, Kaitin KI. Measuring the incidence, causes, and repercussions of protocol amendments. Drug Inf J. 2011;45(3):265–75.CrossRefGoogle Scholar
  20. 20.
    Haidich AB, Ioannidis JP. Effect of early patient enrollment on the time to completion and publication of randomized controlled trials. Am J Epidemiol. 2001;154(9):873–80.CrossRefGoogle Scholar
  21. 21.
    Hewison J, Haines A. Overcoming barriers to recruitment in health research. BMJ. 2006;333(7562):300–2.CrossRefGoogle Scholar
  22. 22.
    Junghans C, Feder G, Hemingway H, Timmis A, Jones M. Recruiting patients to medical research: double blind randomised trial of “opt-in” versus “opt-out” strategies. BMJ. 2005;331(7522):940.CrossRefGoogle Scholar
  23. 23.
    Kaur M, Sprague S, Ignacy T, Thoma A, Bhandari M, Farrokhyar F. How to optimize participant retention and complete follow-up in surgical research. Can J Surg. 2014;57(6):420–7.CrossRefGoogle Scholar
  24. 24.
    Lösch C, Neuhäuser M. The statistical analysis of a clinical trial when a protocol amendment changed the inclusion criteria. BMC Med Res Methodol. 2008;8:16.Google Scholar
  25. 25.
    Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c869.CrossRefGoogle Scholar
  26. 26.
    Ross S, Grant A, Counsell C, Gillespie W, Russell I, Prescott R. Barriers to participation in randomised controlled trials: a systematic review. J Clin Epidemiol. 1999;52(12):1143–56.CrossRefGoogle Scholar
  27. 27.
    Schroy PC 3rd, Glick JT, Robinson P, Lydotes MA, Heeren TC, Prout M, et al. A cost-effectiveness analysis of subject recruitment strategies in the HIPAA era: results from a colorectal cancer screening adherence trial. Clin Trials. 2009;6(6):597–609.CrossRefGoogle Scholar
  28. 28.
    Sweetman EA, Doig GS. Failure to report protocol violations in clinical trials: a threat to internal validity? Trials. 2011;12:214.CrossRefGoogle Scholar
  29. 29.
    Thoma A, Farrokhyar F, McKnight L, Bhandari M. Practical tips for surgical research: how to optimize patient recruitment. Can J Surg. 2010;53(3):205–10.PubMedPubMedCentralGoogle Scholar

Copyright information

© ISAKOS 2019

Authors and Affiliations

  • Caroline Mouton
    • 1
    Email author
  • Laura De Girolamo
    • 2
  • Daniel Theisen
    • 3
  • Romain Seil
    • 1
    • 3
  1. 1.Department of Orthopaedic SurgeryCentre Hospitalier de Luxembourg—Clinique d’EichLuxembourgLuxembourg
  2. 2.Orthopaedic Biotechnology LaboratoryGaleazzi Orthopaedic InstituteMilanItaly
  3. 3.Sports Medicine Research Laboratory, Luxembourg Institute of HealthLuxembourgLuxembourg

Personalised recommendations